Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers for which there are currently limited treatment options. Additionally, Calithera is advancing an investigational, selective oral inhibitor of arginase (CB-280) for the treatment of cystic fibrosis, a first-in-class approach for combating the disease for which there is great need for new treatment approaches.
Quick Links
More information is coming soon.